Rubenstein Gordon

Director Rubenstein Gordon sells 176,709 shares at $11.37 across 3 transactions, reducing stake from 199.4K to 22.7K shares (-88.6%)

Rubenstein Gordon filed a Form 4 on 2026-03-12 disclosing 3 separate sales totaling 176,709 shares for $2,009,778.66, executed at a blended average price of $11.37. This sale reduced his holdings by -88.6%, leaving him with 22,674 shares post-transaction versus 199,383 shares pre-transaction. The timing is noteworthy: his 5 prior trades at ACEL (4 on 2026-03-11 and 1 on 2026-03-10) indicate an active liquidation pattern, though outcomes are not yet measurable. His cross-ticker track record shows 19 prior sells with a 33.33% well-timed rate (average 90d return +8.6%), suggesting mixed timing success historically. The current stock price of $11.15 is -14.6% from the 52-week high, near the bottom of the year's range, which does not align with a pattern of exceptional selling discipline at peaks.

Director Rubenstein Gordon sold 160,561 shares ($1.8M) at $11.38–$11.46 on 2026-03-11, reducing stake by 65.4%.

On 2026-03-11, Director Rubenstein Gordon executed 4 separate sales totaling 160,561 shares (160.6K shares) for $1,827,212.58 ($1.8M) at prices ranging from $11.38 to $11.46, reducing his holdings from 245,333 shares to 84,772 shares (a -65.4% reduction). The blended average sale price of $11.38 is near the current market price of $11.32 and comfortably above the 52-week low of $9.57, but notably 13.3% below the 52-week high of $13.06. Across his cross-ticker track record, Gordon's prior sells have produced an average 90-day return of +9.6%, with a well-timed rate of 28.57%—indicating that most of his historical sells have been preceded or accompanied by stock declines, making the timing of this large liquidation noteworthy. At ACEL specifically, his 5 prior trades are all recent sales with outcomes not yet measurable, so current performance relative to peers or prior patterns at this ticker cannot yet be assessed.

Director Rubenstein Gordon sold 469,885 shares (469.9K shares) for $5,386,489.67 across 5 transactions Mar 6–10, cutting holdings from 607,617 to 137,732 shares (−77.3%).

Rubenstein Gordon executed 5 separate sales totaling 469.9K shares for $5.4M over four trading days (Mar 6–10, 2026), reducing his stake by 77.3% to 137,732 shares remaining. The blended average price of $11.46 sits just 0.9% above the current price of $11.45, despite the stock trading 12.3% below its 52-week high, indicating the sales were executed near recent levels rather than at depressed valuations. His track record at ACEL shows mixed timing: of 5 prior trades at this ticker, only 1 of 4 measurable post-trade 90-day periods showed negative returns (well-timed for a sell). The cross-ticker track record reflects a 16.67% well-timed rate on 16 prior sells, materially below the 100% win rate on his single prior buy; his sells historically underperform directional prediction. With ACEL trading at a P/E of 15.68 and net income of $13.4M against a $933.9M market cap, the company shows fundamental stability. The substantial reduction in Gordon's stake warrants monitoring of any concurrent filings from other board members to assess whether this is director-wide activity or isolated to this executive.

Director Rubenstein Gordon sold 200 shares at $0.00 and bought 200 shares at $0.00 on 2025-03-13 (offsetting transactions).

This Form 4 filing reports two offsetting transactions executed on the same day at $0.00 per share: a sale of 200 shares and a purchase of 200 shares, leaving Rubenstein Gordon with 2,950 shares post-transaction. The zero-dollar transaction prices indicate these are likely non-cash corporate actions (such as option exercises, restricted stock vesting, or plan-related adjustments) rather than open-market trades, as no consideration changed hands. With ACEL's stock at $9.82 current price and down 21.2% from its 52-week high of $12.47, the director's net position remains functionally unchanged, and the structure does not reveal discretionary buying or selling conviction.